Stock of the Day

June 19, 2020

Merus (MRUS)

$90.00
-$6.92 (-7.1%)
Market Cap: $6.83B

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Today's Trend

Merus N.V. (MRUS) — The stock is trading lower today on heavy volume. Investors are reacting to a mix of strong insider/acquirer buying by major shareholder A/S Genmab (bullish signal) and a material corporate action — completion of Genmab’s acquisition and reported Nasdaq delisting (liquidity/float concerns). Short‑term volatility has been amplified by a trading halt and elevated options flows.

  • A/S Genmab has accumulated very large blocks of Merus stock across Dec. 16–29 (including a 1,052,806‑share purchase on Dec. 29 at ~$97/share), raising its stake into the tens of millions of shares — a strong signal of buyer conviction that can underpin the share price. SEC Ownership Filing
  • Other institutional investors have also added positions recently, indicating continued institutional interest that supports longer‑term valuation despite near‑term noise. MarketBeat Institutional Ownership
  • Trading in MRUS was temporarily halted for “news pending,” a procedural event that often precedes material announcements and typically increases intraday volatility without indicating direction.
  • Unusually large options activity has been reported in MRUS, which can reflect speculative positioning or hedging and tends to raise short‑term volatility but is ambiguous for a sustained direction. Options Flow Report
  • Reports that Merus has completed the Genmab acquisition and will be delisted from Nasdaq are material — delisting reduces public float and liquidity, can force some holders to sell, and often prompts re‑pricing; this is a likely driver of the intraday sell‑off. TipRanks: Acquisition/Delisting

Bottom line for investors: sizeable insider/acquirer buying is bullish for fundamentals and signals confidence, but the acquisition/delisting is an immediate negative for liquidity and may trigger forced repositioning — together these forces explain the heavy selling and higher volume today. Monitor SEC filings for final ownership numbers and any official delisting timetable from the company or exchange.